New compound may accelerate bone healing, prevent osteoporosis

August 17, 2011, Indiana University

An Indiana University scientist studying human bone growth has received a $2.6 million grant from the U.S. Department of Defense to study a chemical compound with potential to fight osteoporosis and accelerate broken bone healing.

Hiroki Yokota, professor of biomedical engineering at Indiana University-Purdue University Indianapolis (IUPUI) and adjunct professor of anatomy and cell biology at the IU School of Medicine, will investigate the effect of salubrinal -- a originally developed to encourage in individuals with diabetes -- on strength and growth. Early laboratory research supported by the Indiana Clinical and Translational Sciences Institute (CTSI) suggests weakened bones treated with salubrinal experience a statistically significant increase in strength, as well as accelerated healing in bones that have been fractured.

"People are getting older," Yokota said, "and when people get older, particularly women, they tend to develop osteoporotic bones. As a , I was originally exploring mechanical stimulation, which is similar to exercise, to strengthen bones. But by studying these mechanisms, I came across a molecular pathway that became the beginning of this discovery."

Acute pelvic and hip fractures account for about 350,000 hospitalizations each year in the United States, with 76 percent of patients being female and annual cases expected to reach 650,000 by 2050. Moreover, Yokota said approximately 25 percent of fracture patients previously living independently require full-time nursing care post-fracture, with only a quarter returning to pre-injury levels of activity and half never fully recovering.

Older populations are increasingly affected by weakened and broken bones as aging cells are no longer able to produce sufficient levels of collagen, the protein from which bones derive their strength. Salubrinal prevents this cellular decline by strengthening the body's "protein-producing machinery," which creates collagen and keeps bones strong.

"In preliminary studies, particularly in bone fractures, we've see an effect in as little as a week," said Yokota, "and the effect is even stronger in two weeks. We're not ready to cite numbers, but I can say it appears significant."

The process by which salubrinal heals fractures may also apply to type 2 diabetes, the disease for which salubrinal was originally conceived.

"Salubrinal stimulates a cellular 'rescue program' in response to stress," said Yokota, noting some diabetes may be caused by the pancreas killing insulin-producing eyelet cells in response to increased insulin needs -- a process similar to the cellular shutdown that can occur in bones overtaxed by collagen production.

"With this drug," Yokota said, "the cells just enjoy the body's rescue response without really experiencing any new negative pressure. Using salubrinal is basically about trying to treat cells a little better."

The Department of Defense grant will support continued research into the effectiveness of salubrinal on broken and weakened bones and contribute to determining dosing guidelines, said Yokota, with an eye toward moving the drug into early clinical trials for patients with osteoporosis or bone fractures.

"In a sense, step one is done," he said. "This support will move us towards step two."

Developing a pill from the compound's current, injectable form -- making it easier to administer as well as increase its potential marketability -- is also a priority.

Altogether, Yokota sets an ambitious agenda.

"Our ultimate goal is FDA approval to provide a safe, efficacious, easy-to-use drug therapy that will heal hip fractures in the geriatric population," he said.

Additional support for Yokota's other projects related to and growth comes from the National Institutes of Health and the National Aeronautics and Space Administration, which has invested in his research for its potential to reduce bone loss experienced by astronauts due to weightlessness.

The Indiana CTSI provided key support to Yokota's early investigation into salubrinal with a $20,000 Research Inventions and Scientific Commercialization Grant. The funds fueled research identifying a chemical partner that combines with the salubrinal to create a safe, non-toxic drug easily absorbable by the human body. The early study also benefitted from a program managed by the Indiana CTSI, in partnership with the IU Kelley School of Business, which partners investigators looking to turn their discoveries into viable startup projects with MBA students seeking real-life experience in the business of life science.

Explore further: Stem cell treatment may offer option for broken bones that don't heal

Related Stories

Stem cell treatment may offer option for broken bones that don't heal

June 5, 2011
Researchers at the University of North Carolina at Chapel Hill School of Medicine have shown in an animal study that transplantation of adult stem cells enriched with a bone-regenerating hormone can help mend bone fractures ...

Recommended for you

Bioengineered soft microfibers improve T-cell production

January 18, 2018
T cells play a key role in the body's immune response against pathogens. As a new class of therapeutic approaches, T cells are being harnessed to fight cancer, promising more precise, longer-lasting mitigation than traditional, ...

Weight flux alters molecular profile, study finds

January 17, 2018
The human body undergoes dramatic changes during even short periods of weight gain and loss, according to a study led by researchers at the Stanford University School of Medicine.

Secrets of longevity protein revealed in new study

January 17, 2018
Named after the Greek goddess who spun the thread of life, Klotho proteins play an important role in the regulation of longevity and metabolism. In a recent Yale-led study, researchers revealed the three-dimensional structure ...

The HLF gene protects blood stem cells by maintaining them in a resting state

January 17, 2018
The HLF gene is necessary for maintaining blood stem cells in a resting state, which is crucial for ensuring normal blood production. This has been shown by a new research study from Lund University in Sweden published in ...

Magnetically applied MicroRNAs could one day help relieve constipation

January 17, 2018
Constipation is an underestimated and debilitating medical issue related to the opioid epidemic. As a growing concern, researchers look to new tools to help patients with this side effect of opioid use and aging.

Researchers devise decoy molecule to block pain where it starts

January 16, 2018
For anyone who has accidentally injured themselves, Dr. Zachary Campbell not only sympathizes, he's developing new ways to blunt pain.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.